Spring is a miserable season for those with seasonal allergies. There are effective drug- and non-drug measures that can ...

A research team has introduced a new out-of-core mechanism, Capsule, for large-scale GNN training, which can achieve up to a 12.02× improvement in runtime efficiency, while using only 22.24% of the ...

Dr. Ransom is a graduate of the University of Iowa College of Medicine (1962) and was certified by the American Board of Allergy and Immunology in 1974. He is a Fellow of the American College of ...

A RECENT review has brought to light the growing concern over climate change and its influence on allergic rhinitis (AR), a common inflammatory upper airway condition. Synthesising evidence from 30 ...

Nasdepi® is a dry powder formulation of epinephrine being developed for intranasal administration to treat Type 1 allergic reactions including anaphylaxis. Nasdepi® remains to have the potential ...

Administration of Nasdepi® after inducting allergic rhinitis with an allergen challenge resulted in more rapid drug exposures and comparable pharmacologic responses compared to subjects without ...

Clinical trials are the best indicator of the effectiveness, safety and tolerability of an antihistamine in the treatment of allergic diseases. In contrast to controlled allergen chamber studies ...

However, the neural mechanisms that support the ability to credit only those past choices believed to have caused the observed outcomes remain unclear. Here, we leverage multivariate pattern analyses ...

Scott Lyman, CEO of Belhaven Biopharma, expressed enthusiasm about the results, stating, "The successful outcomes of this dose confirmation and allergic rhinitis study clears the way for our pivotal ...